Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,410 full-time employees.  The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.

Regeneron Pharmaceuticals, Inc. adalah perusahaan bioteknologi yang terlibat dalam penemuan, invensi, pengembangan, manufaktur, dan komersialisasi obat-obatan. Perusahaan ini berkantor pusat di Tarrytown, New York dan saat ini mempekerjakan 15.410 karyawan penuh waktu. Perusahaan ini menciptakan, mengembangkan, memproduksi, dan mengkomersialkan obat-obatan untuk orang-orang dengan penyakit serius. Produk dan kandidat produk yang sedang dikembangkan dirancang untuk membantu pasien dengan penyakit mata, penyakit alergi dan inflamasi, kanker, penyakit kardiovaskular dan metabolik, penyakit neurologis, kondisi hematologis, penyakit menular, dan penyakit langka. Perusahaan ini mempercepat pengembangan obat dengan menggunakan teknologi kepemilikannya, seperti VelociSuite, yang memproduksi antibodi manusia penuh yang dioptimalkan dan kelas baru antibodi bispesifik. VelociSuite terdiri dari VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, dan teknologi terkait lainnya. Produk yang sudah dipasarkan mencakup EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, dan lainnya.

Regeneron

NVIDIA

Google

Apple

Microsoft

Amazon

Broadcom

Taiwan Semiconductor

Tesla

Meta Platforms

Walmart

Berkshire Hathaway

Eli Lilly

Micron Technology

JPMorgan

Exxon Mobil

Visa

ASML

Oracle

Intel

Johnson & Johnson

Cisco

Costco

MasterCard

SPDR S&P500 ETF

Caterpillar

Chevron

AbbVie

Netflix

UnitedHealth Group

Lam Research

Bank of America

Coca-Cola

Applied Materials

Alibaba

Procter & Gamble

Palantir

Morgan Stanley

Vanguard Total Stock Market ETF

Home Depot

Philip Morris

General Electric

AstraZeneca

Goldman Sachs

Texas Instruments

Merck

Novartis

Royal Bank of Canada

Toyota

Wells Fargo

Shell

Linde PLC

Raytheon Technologies

American Express

QUALCOMM

Citigroup

Novo Nordisk

TotalEnergies

Analog Devices

PepsiCo

Invesco QQQ Trust

T-Mobile

Verizon

Palo Alto Networks

McDonald's

NextEra Energy

Toronto-Dominion Bank

Arista Networks

Disney

Seagate Technology

Amgen

Boeing

Banco Santander

BlackRock

AT&T

Corning

Gilead Sciences

Western Digital

Anheuser-Busch Inbev

Union Pacific

Charles Schwab

Dell

Marvell Technology

Uber

Deere

CrowdStrike

Intuitive Surgical

ConocoPhillips

Southern Copper

Abbott

Pfizer

Blackstone

Salesforce

British American Tobacco

Honeywell

Regeneron Stock

About Regeneron

Key Statistics

Insights

People Also Bought